Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Hengli botulinum toxin type A injection for primary axillary hyperhidrosis
CTR20220601Phase 3Active
- Sponsor
- Lanzhou Biotechnology Development
- Start
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of lanbotulinumtoxin-A in essential axillary hyperhidrosis, sponsored by Lanzhou Biotechnology Development. Started Apr 2022; status: active.
02
Drugs
lanbotulinumtoxin-A
03
Conditions
essential axillary hyperhidrosis
Beyond the preview
Go deeper on CTR20220601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220601.